Taiwan’s Biotech Sector Eyes a Breakthrough: Medigen Forms NK Cell Therapy Alliance

Taiwan’s biotechnology industry may be on the verge of a major breakthrough. On the 4th, Medigen announced a strategic alliance with ApexBio and Xianjin Intelligence, targeting the development of therapies based on NK cells, often referred to as the body’s natural cancer fighters.

Medigen founder Ming-Chih Hsuan has set an ambitious timeline, stating that the treatment solution — which integrates AI technology with patented cell expansion methods — aims to be implemented as early as the end of this year.

What Are NK Cells? The Immune System’s “Special Forces”

NK cells, short for Natural Killer cells, are a type of immune cell that plays a critical role in defending the body.

Imagine the immune system as a military force — NK cells act as its special operations unit. Unlike many other immune cells, they do not require complex identification processes to recognize threats. As they patrol the body, once they detect cancerous or virus-infected cells, they can immediately attack and destroy them.

Why Target Umbilical Cord Blood–Derived NK Cells?

Medigen has chosen to focus on NK cells derived from umbilical cord blood, mainly for two reasons.

First, these cells are relatively younger and more active, giving them stronger therapeutic potential.

Second, they are less likely to trigger serious immune reactions, such as immune rejection or cytokine storms—a condition in which the immune system becomes dangerously overactive.

These advantages make cord blood–derived NK cells well suited for allogeneic therapy, meaning cells from one individual can be used to treat another. This avoids the lengthy process of cultivating a patient’s own cells, which is often required in traditional cell therapies.

ApexBio’s Patented Platform: Building an NK Cell “Army”

One of the biggest challenges in NK cell therapy has long been insufficient cell supply.

Although cord blood is a promising source, the number of NK cells it contains is relatively small, making it difficult to support large-scale clinical use.

ApexBio’s patented ApexNK® platform acts like a superfactory for cells. Within a closed and controlled environment, it can expand valuable NK cell “seeds” by hundreds of thousands of times.

This technology addresses the long-standing challenge of limited starting cell quantities, paving the way for large-scale production and making NK cell therapy more accessible rather than a luxury available to only a few patients.

AI from Xianjin Intelligence: A Precision Medicine “Radar System”

Having enough therapeutic cells is only part of the solution — precision targeting and monitoring are equally critical.

Xianjin Intelligence introduces AI-powered technology that enables Medigen to build an immune cell data analysis system, functioning as a sophisticated radar for this NK cell “force.”

Traditional immune data analysis can be time-consuming and prone to human error. AI systems can automatically interpret complex datasets, significantly shortening analysis time while accurately evaluating a patient’s immune health and disease risk.

As a result, each treatment report can become more standardized, consistent, and precise, bringing the vision of personalized health management closer to reality.

A Powerful Alliance: Medigen Sets Its Sights on the Global Stage

Hsuan Ming-Chih expressed strong confidence in the partnership among the three companies.

He pointed out that biotechnology differs from the semiconductor industry in a key way: biotech innovations can first be implemented, validated, and refined locally in Taiwan, leveraging the country’s world-class medical system before expanding globally.

“Through AI and modular manufacturing processes, we aim not only to innovate technologically, but also to ensure that the value of cell therapy becomes visible and accessible to more people,” Hsuan said.

With optimized manufacturing processes and AI-based diagnostics now in place, Medigen believes it is ready to elevate Taiwan’s biotech capabilities and compete on the global stage.